Tumor location and patient age predict biological signatures of high-grade gliomas

Neurosurg Rev. 2018 Apr;41(2):599-604. doi: 10.1007/s10143-017-0899-8. Epub 2017 Aug 31.

Abstract

Prognostic factors for high-grade gliomas include patient age, IDH1 mutation, MGMT methylation, and Ki67 value. We assessed the predictive role of topographic location of gliomas for their biological signatures. Collecting all neuroradiological and histological data of patients with histologically proven HGG, we performed a retrospective monocentric study. A predictive value of frontal location for a lower Ki67 value (especially in the left hemisphere) and mutation of IDH1 (especially in the right hemisphere) was found. Temporal location was predictive for IDH1 wild-type. Involvement of the parietal lobe was found to be predictive of methylated MGMT, while insular lobe involvement predicted an unmethylated MGMT. There was no statistically significant difference of IDH1 mutation and MGMT methylation between left and right sides.

Keywords: Glioblastoma; Glioma; High-grade glioma; IDH1, MGMT, Ki67; Low-grade glioma.

MeSH terms

  • Adult
  • Age Factors
  • Aged
  • Brain Neoplasms / genetics
  • Brain Neoplasms / metabolism*
  • Brain Neoplasms / pathology*
  • DNA Methylation
  • DNA Modification Methylases / metabolism
  • DNA Repair Enzymes / metabolism
  • Female
  • Glioma / genetics
  • Glioma / metabolism*
  • Glioma / pathology*
  • Humans
  • Isocitrate Dehydrogenase / genetics
  • Ki-67 Antigen / metabolism
  • Male
  • Middle Aged
  • Mutation
  • Neoplasm Grading
  • Prognosis
  • Promoter Regions, Genetic
  • Retrospective Studies
  • Tumor Suppressor Proteins / genetics
  • Tumor Suppressor Proteins / metabolism

Substances

  • Ki-67 Antigen
  • Tumor Suppressor Proteins
  • Isocitrate Dehydrogenase
  • IDH1 protein, human
  • DNA Modification Methylases
  • MGMT protein, human
  • DNA Repair Enzymes